Elsevier

Lung Cancer

Volume 21, Issue 2, August 1998, Pages 105-113
Lung Cancer

Prevalence of co-morbidity in lung cancer patients and its relationship with treatment: A population-based study

https://doi.org/10.1016/S0169-5002(98)00039-7Get rights and content

Abstract

Background: With the rising mean age of lung cancer patients, the number of patients with serious co-morbidity at diagnosis is increasing. As a result, co-morbidity may become an important factor in both the choice of treatment and survival. We studied the prevalence of serious co-morbidity among newly diagnosed lung cancer patients and its association with morphology, stage and treatment. Patients: A total of 3864 lung cancer patients registered in the population-based registry of the Comprehensive Cancer Centre South between 1993 and 1995. Results: During the study period, the mean age of patients was 67 years (range: 29–93). The most frequent concomitant diseases were cardiovascular diseases (23%), chronic obstructive pulmonary diseases (COPD) (22%) and other malignancies (15%). The prevalence of concomitant diseases was highest for men (60%), patients with squamous-cell carcinoma (64%) and those with a localised tumour (66%). The resection rate for patients <70 years, with a localised non-small-cell lung tumour, was especially low for those with COPD (67%) or diabetes (64%) compared with patients without concomitant diseases (94%). The association between co-morbidity and chemotherapy for patients with small-cell lung cancer was limited. Conclusions: The prevalence of co-morbidity, especially cardiovascular diseases and COPD, among lung cancer patients is about twice as high as in the general population. Co-morbidity seems to be associated with earlier diagnosis of lung cancer, but it may also lead to less accurate staging and less aggressive treatment. Thus, prognosis is likely to be negatively influenced by co-morbidity.

Introduction

Lung cancer is the most common type of cancer among men in The Netherlands and ranks third for women; incidence increases sharply with age [1]. With the rising mean age of lung cancer patients diagnosed in southeastern Netherlands from 61 years in 1960 to 67 years in 1995, care for cancer patients with serious concomitant diseases is becoming increasingly complex, because of complications and quality-of-life after treatment 2, 3, 4, 5. The prognosis for patients with co-morbidity may also be worse, independent of age, disease stage and type of treatment 6, 7, 8. The Eindhoven Cancer Registry, at the request of clinicians, has been collecting data on clinically relevant concomitant diseases for all cancer patients since 1993. We analysed the age-specific prevalence of serious co-morbidity for lung cancer patients in relation to cancer morphology, stage of disease and treatment. Since mortality in our area, especially due to tobacco-related causes of death such as respiratory diseases, cancer and cardiovascular diseases, is almost twice as high for men as women [9], we evaluated the prevalence of co-morbidity for each sex separately.

Section snippets

Patients and methods

Data were derived from the Eindhoven Cancer Registry, which has collected data on patients with newly diagnosed cancer since 1955 in the Dutch province of North Brabant and since 1970 also in the northern part of the adjacent province of Limburg. This registry serves a population of about 2 million inhabitants. The access to specialized care is good, supplied by 16 community hospitals and two large radiotherapy Institutes. Data on clinically relevant concomitant diseases, noted in the clinical

Prevalence of co-morbidity

Between 1993 and 1995, 3864 lung cancer patients were diagnosed (3183 men and 681 women), whereas 3551 serious concomitant conditions in 2258 patients were recorded; 34% of patients did not have a concomitant disease and the existence of other diseases was unknown in 8% of cases. The mean age of patients was 67 years (range: 29–93).

The prevalence of co-morbidity for lung cancer patients of ≥70 years (69%) was higher than for younger patients (52%) (P=0.001) (Table 2). Fig. 1 shows the

Discussion

The most common concomitant diseases among patients with lung cancer were cardiovascular diseases, COPD, other malignancies, hypertension and diabetes mellitus; the prevalences were the highest for men, patients with squamous-cell carcinoma and those with a localised tumour. As expected, the prevalence increased with age. The resection rate for patients with a localised non-small-cell lung tumour decreased with an increasing number of concomitant diseases, whereas the percentage undergoing

Conclusion

The prevalence of co-morbidity, especially cardiovascular diseases and COPD, among lung cancer patients is approximately twice as high as in the general population. Co-morbidity is associated with earlier diagnosis of lung cancer, but it may also lead to less accurate staging and less aggressive treatment. Thus prognosis is likely to be negatively influenced by co-morbidity.

Acknowledgements

We thank the chest physicians of the St. Joseph, St. Anna and Catharina Hospitals for participation in the validation study and the registration team for data collection.

References (34)

  • JF Piccirillo et al.

    Clinical symptoms and comorbidity: significance for the prognostic classification of cancer

    Cancer

    (1996)
  • AR Feinstein et al.

    A clinical-severity staging system for patients with lung cancer

    Medicine

    (1990)
  • Coebergh JWW, van der Heijden LH, Janssen-Heijnen MLG. Cancer incidence and survival in the south-east of the...
  • ME Charlson et al.

    A new method of classifying prognostic comorbidity in longitudinal studies: development and validation

    J Chron Dis

    (1987)
  • The World Health Organization histological typing of lung tumours

    Am J Clin Path

    (1982)
  • CF Mountain

    A new international staging system for lung cancer

    Chest

    (1986)
  • SJ Looman et al.

    Stroke in the elderly; prevalence and frequency of hospitalization; the Rotterdam study (in Dutch)

    Ned Tijdschr Geneeskd

    (1996)
  • Cited by (268)

    • Comment optimiser le bilan d'opérabilité ?

      2023, Revue des Maladies Respiratoires Actualites
    View all citing articles on Scopus
    View full text